Nanomolar Inhibitors of Glycogen Phosphorylase Based on β-<scp>d</scp>-Glucosaminyl Heterocycles: A Combined Synthetic, Enzyme Kinetic, and Protein Crystallography Study
作者:Éva Bokor、Efthimios Kyriakis、Theodora G.A. Solovou、Csenge Koppány、Anastassia L. Kantsadi、Katalin E. Szabó、Andrea Szakács、George A. Stravodimos、Tibor Docsa、Vassiliki T. Skamnaki、Spyros E. Zographos、Pál Gergely、Demetres D. Leonidas、László Somsák
DOI:10.1021/acs.jmedchem.7b01056
日期:2017.11.22
C-β-d-glucosaminyl 1,2,4-triazoles and imidazoles were synthesized and tested as inhibitors against muscle and liver isoforms of glycogen phosphorylase (GP). While the N-β-d-glucosaminyl 1,2,3-triazoles showed weak or no inhibition, the C-β-d-glucosaminyl derivatives had potent activity, and the best inhibitor was the 2-(β-d-glucosaminyl)-4(5)-(2-naphthyl)-imidazole with a Ki value of 143 nM against human liver
芳基取代的1-(β- d -glucosaminyl)-1,2,3-三唑以及Ç -β- d -glucosaminyl 1,2,4-三唑类和咪唑的合成和作为对抗的肌肉和肝脏同种型抑制剂测试糖原磷酸化酶(GP)。虽然Ñ -β- d -glucosaminyl 1,2,3-三唑呈弱或无抑制,所述Ç -β- d -glucosaminyl衍生物具有有效的活性,而最好的抑制剂是2-(β- d -glucosaminyl)具有K i的-4(5)-(2-萘基)-咪唑抗人肝GPa值143 nM。兔肌肉GPb抑制剂复合物的X射线晶体学研究揭示了强结合的结构特征,并为葡萄糖基和糖胺基衍生物之间的抑制力差异以及咪唑与1,2,4-三唑之间的差异提供了解释类似物。